144 related articles for article (PubMed ID: 35687360)
1. Clinicopathologic and Immunohistochemical Characterization of Sarcomatoid Chromophobe Renal Cell Carcinoma: An Analysis of 22 Cases.
Whaley RD; Cheng L
Am J Surg Pathol; 2022 Sep; 46(9):1171-1179. PubMed ID: 35687360
[TBL] [Abstract][Full Text] [Related]
2. Distinct immunophenotypes and prognostic factors in renal cell carcinoma with sarcomatoid differentiation: a systematic study of 19 immunohistochemical markers in 42 cases.
Yu W; Wang Y; Jiang Y; Zhang W; Li Y
BMC Cancer; 2017 Apr; 17(1):293. PubMed ID: 28449664
[TBL] [Abstract][Full Text] [Related]
3. Differential immunohistochemical and molecular profiling of conventional and aggressive components of chromophobe renal cell carcinoma: pitfalls for diagnosis.
Chen CV; Croom NA; Simko JP; Stohr BA; Chan E
Hum Pathol; 2022 Jan; 119():85-93. PubMed ID: 34800526
[TBL] [Abstract][Full Text] [Related]
4. DOG1, cyclin D1, CK7, CD117 and vimentin are useful immunohistochemical markers in distinguishing chromophobe renal cell carcinoma from clear cell renal cell carcinoma and renal oncocytoma.
Zhao W; Tian B; Wu C; Peng Y; Wang H; Gu WL; Gao FH
Pathol Res Pract; 2015 Apr; 211(4):303-7. PubMed ID: 25596994
[TBL] [Abstract][Full Text] [Related]
5. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
[TBL] [Abstract][Full Text] [Related]
6. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases.
de Peralta-Venturina M; Moch H; Amin M; Tamboli P; Hailemariam S; Mihatsch M; Javidan J; Stricker H; Ro JY; Amin MB
Am J Surg Pathol; 2001 Mar; 25(3):275-84. PubMed ID: 11224597
[TBL] [Abstract][Full Text] [Related]
7. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
8. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
[TBL] [Abstract][Full Text] [Related]
9. Programmed death ligand 1/indoleamine 2,3-dioxygenase 1 expression and tumor-infiltrating lymphocyte status in renal cell carcinoma with sarcomatoid changes and rhabdoid features.
Kiyozawa D; Takamatsu D; Kohashi K; Kinoshita F; Ishihara S; Toda Y; Eto M; Oda Y
Hum Pathol; 2020 Jul; 101():31-39. PubMed ID: 32360490
[TBL] [Abstract][Full Text] [Related]
10. Genetic Profiling Uncovers Genome-Wide Loss of Heterozygosity and Provides Insight into Mechanisms of Sarcomatoid Transformation in Chromophobe Renal Cell Carcinoma.
Collins K; Acosta AM; Siegmund SE; Cheng L; Hirsch MS; Idrees MT
Mod Pathol; 2024 Feb; 37(2):100396. PubMed ID: 38043790
[TBL] [Abstract][Full Text] [Related]
11. [Clinicopathological features and prognosis of renal cell carcinoma with sarcomatoid differentiation].
Jiang Y; Su G; Yu W; Li J; Lu Q; Li Y; Zhang W
Zhonghua Zhong Liu Za Zhi; 2015 Nov; 37(11):823-6. PubMed ID: 26887511
[TBL] [Abstract][Full Text] [Related]
12. Chromophobe Renal Cell Carcinoma with Sarcomatoid Differentiation: Clinicopathologic Correlation and Molecular Findings.
Gama A; Xu H; Yang XJ; Choy B
Int J Surg Pathol; 2024 Feb; 32(1):11-16. PubMed ID: 37063043
[No Abstract] [Full Text] [Related]
13. Non-small cell lung carcinomas with a minor sarcomatoid component and pleomorphic carcinomas are associated with high expression of programmed death ligand 1.
Tancoš V; Farkašová A; Kviatkovská Z; Grendár M; Líšková A; Huťka Z; Plank L
Pathol Res Pract; 2020 Dec; 216(12):153238. PubMed ID: 33059241
[TBL] [Abstract][Full Text] [Related]
14. Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features.
McGregor BA; McKay RR; Braun DA; Werner L; Gray K; Flaifel A; Signoretti S; Hirsch MS; Steinharter JA; Bakouny Z; Flippot R; Wei XX; Choudhury A; Kilbridge K; Freeman GJ; Van Allen EM; Harshman LC; McDermott DF; Vaishampayan U; Choueiri TK
J Clin Oncol; 2020 Jan; 38(1):63-70. PubMed ID: 31721643
[TBL] [Abstract][Full Text] [Related]
15. Sarcomatoid renal cell carcinoma with foci of chromophobe carcinoma.
Cserni G; Kovács BR; Tarján M; Sápi Z; Domján Z; Szabó Z
Pathol Oncol Res; 2002; 8(2):142-4. PubMed ID: 12172580
[TBL] [Abstract][Full Text] [Related]
16. Sarcomatoid renal cell carcinoma: the chromophobe connection.
Akhtar M; Tulbah A; Kardar AH; Ali MA
Am J Surg Pathol; 1997 Oct; 21(10):1188-95. PubMed ID: 9331291
[TBL] [Abstract][Full Text] [Related]
17. JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management.
Gupta S; Cheville JC; Jungbluth AA; Zhang Y; Zhang L; Chen YB; Tickoo SK; Fine SW; Gopalan A; Al-Ahmadie HA; Sirintrapun SJ; Blum KA; Lohse CM; Hakimi AA; Thompson RH; Leibovich BC; Berger MF; Arcila ME; Ross DS; Ladanyi M; Antonescu CR; Reuter VE
Mod Pathol; 2019 Sep; 32(9):1344-1358. PubMed ID: 30996253
[TBL] [Abstract][Full Text] [Related]
18. Use of PAX8 and GATA3 in diagnosing sarcomatoid renal cell carcinoma and sarcomatoid urothelial carcinoma.
Chang A; Brimo F; Montgomery EA; Epstein JI
Hum Pathol; 2013 Aug; 44(8):1563-8. PubMed ID: 23453625
[TBL] [Abstract][Full Text] [Related]
19. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.
McKay RR; Bossé D; Xie W; Wankowicz SAM; Flaifel A; Brandao R; Lalani AA; Martini DJ; Wei XX; Braun DA; Van Allen E; Castellano D; De Velasco G; Wells JC; Heng DY; Fay AP; Schutz FA; Hsu J; Pal SK; Lee JL; Hsieh JJ; Harshman LC; Signoretti S; Motzer RJ; Feldman D; Choueiri TK
Cancer Immunol Res; 2018 Jul; 6(7):758-765. PubMed ID: 29748390
[TBL] [Abstract][Full Text] [Related]
20. Chromosomal gains in the sarcomatoid transformation of chromophobe renal cell carcinoma.
Brunelli M; Gobbo S; Cossu-Rocca P; Cheng L; Hes O; Delahunt B; Pea M; Bonetti F; Mina MM; Ficarra V; Chilosi M; Eble JN; Menestrina F; Martignoni G
Mod Pathol; 2007 Mar; 20(3):303-9. PubMed ID: 17277768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]